Vargatef (nintedanib)
- Region
- 🇪🇺 EU
- Active substance
- nintedanib
- Company
- Boehringer Ingelheim International GmbH
- Status
- Authorised
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Thu 25 Sep 2014
- EU approval
- Fri 21 Nov 2014
- Application
- EMEA/H/C/002569
- ATC
- L01EX09
- Official record
- www.ema.europa.eu
Indication
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ofev Authorised · Boehringer Ingelheim International GmbH
- 🇪🇺 Nintedanib Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Nintedanib Viatris Authorised · Viatris Limited
Follow Vargatef
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.